Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

NovaBay Pharmaceuticals (NBY) Receivables - Other (2018 - 2022)

NovaBay Pharmaceuticals (NBY) has disclosed Receivables - Other for 5 consecutive years, with $11000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Receivables - Other fell 89.0% to $11000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $11000.0, a 89.0% decrease, with the full-year FY2021 number at $100000.0, down 50.0% from a year prior.
  • Receivables - Other was $11000.0 for Q3 2022 at NovaBay Pharmaceuticals, down from $100000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $321000.0 in Q1 2021 to a low of $6000.0 in Q1 2019.
  • A 5-year average of $108583.3 and a median of $100000.0 in 2021 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: surged 2783.33% in 2020, then plummeted 89.0% in 2022.
  • NovaBay Pharmaceuticals' Receivables - Other stood at $39000.0 in 2018, then soared by 271.79% to $145000.0 in 2019, then dropped by 0.69% to $144000.0 in 2020, then tumbled by 86.81% to $19000.0 in 2021, then tumbled by 42.11% to $11000.0 in 2022.
  • Per Business Quant, the three most recent readings for NBY's Receivables - Other are $11000.0 (Q3 2022), $100000.0 (Q1 2022), and $19000.0 (Q4 2021).